- Home
- CLLS vs CADL Comparison
CLLS vs CADL Comparison
Compare CLLS & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- CADL
- Stock Information
- Founded
- CLLS 1999
- CADL 1999
- Country
- CLLS France
- CADL United States
- Employees
- CLLS N/A
- CADL N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- CADL Biotechnology: Pharmaceutical Preparations
- Sector
- CLLS Health Care
- CADL Health Care
- Exchange
- CLLS Nasdaq
- CADL Nasdaq
- Market Cap
- CLLS 299.0M
- CADL 339.8M
- IPO Year
- CLLS 2007
- CADL 2021
- Fundamental
- Price
- CLLS $3.85
- CADL $4.67
- Analyst Decision
- CLLS Buy
- CADL Strong Buy
- Analyst Count
- CLLS 1
- CADL 7
- Target Price
- CLLS $8.00
- CADL $19.43
- AVG Volume (30 Days)
- CLLS 73.5K
- CADL 642.2K
- Earning Date
- CLLS 11-07-2025
- CADL 11-13-2025
- Dividend Yield
- CLLS N/A
- CADL N/A
- EPS Growth
- CLLS N/A
- CADL N/A
- EPS
- CLLS N/A
- CADL N/A
- Revenue
- CLLS $82,551,000.00
- CADL N/A
- Revenue This Year
- CLLS N/A
- CADL N/A
- Revenue Next Year
- CLLS $58.00
- CADL N/A
- P/E Ratio
- CLLS N/A
- CADL N/A
- Revenue Growth
- CLLS 129.04
- CADL N/A
- 52 Week Low
- CLLS $1.10
- CADL $3.79
- 52 Week High
- CLLS $5.48
- CADL $14.60
- Technical
- Relative Strength Index (RSI)
- CLLS 58.54
- CADL 34.79
- Support Level
- CLLS $3.49
- CADL $4.46
- Resistance Level
- CLLS $3.86
- CADL $5.32
- Average True Range (ATR)
- CLLS 0.22
- CADL 0.27
- MACD
- CLLS 0.03
- CADL -0.07
- Stochastic Oscillator
- CLLS 89.76
- CADL 13.43
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.